PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50122C00079Objective of THIS contract IS to — Orasure Technologies, Inc

Orasure Technologies, Inc holds $6.7M across 45 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award in the incumbent pipeline. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Jun 30, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Orasure Technologies, Inc

Recipient

Jun 30, 2027

PoP end

$15.5M

Obligated

$15.5M

Potential

541714

NAICS

AN13

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Orasure Technologies, Inc — $90

Contract facts

NONE

Contract number75A50122C00079

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentOrasure Technologies, Inc

CAGE0PNX6

UEIY79RWFLHWDM6

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performanceBETHLEHEM PA

Pricing typeCost Plus Fixed Fee

Extent competedNot Competed

Related solicitation75A50122R00024

PoP startJan 3, 2023

PoP end (current)Jun 30, 2027

Obligated$15.5M

Current value$15.5M

Potential value$15.5M

THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Orasure Technologies, Inc. Estimated value $15.5M ($15.5M obligated). Current period of performance ends Jun 30, 2027. Last award drew 1 bidder. Place of performance: BETHLEHEM PA. Related solicitation 75A50122R00024.

Recompete timing

Public

● Expiring in 312 days

Current PoP ends Jun 30, 2027 (312 days remaining). Agencies typically plan 12–18 months ahead — at 10.2 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Orasure Technologies, Inc — $6.7M obligated across 45 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$6.7M · 100% of firm total

Open full company profile →

Related awards

Same incumbent

75A50122P00014

THE PURPOSE OF THIS PURCHASE ORDER IS TO PROCURE ANTIBODY AND DIAGNOSTIC TESTS TO DETECT E…

$1.1M

Jun 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50122C00079?

75A50122C00079 (Objective of THIS contract IS to) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $15.5M, currently held by Orasure Technologies, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50122C00079?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50122C00079 to Orasure Technologies, Inc (potential $15.5M).

Who is the incumbent on 75A50122C00079?

Orasure Technologies, Inc is the incumbent with $6.7M across 45 related awards in SCOUT’s public footprint. The current period of performance ends Jun 30, 2027.

When does Orasure Technologies, Inc’s 75A50122C00079 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Sep 4, 2025